LGC Acquires Virusys Corp, Expanding Infectious Disease Portfolio

10 October 2023 | Tuesday | News

LGC Clinical Diagnostics, a business unit of LGC, announced the acquisition of Virusys Corporation, a developer and manufacturer of monoclonal antibodies and viral antigens.

Virusys’ monoclonal antibody technologies and virology expertise are highly complementary to LGC Clinical Diagnostics’ existing antigen product portfolio and will enable LGC to provide customers with antibody technologies to accelerate their infectious disease research programmes, including influenza A and B, herpes simplex viruses and varicella zoster, which can cause diseases like chickenpox and shingles.

Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics, said, “We are excited about the additional scientific expertise Virusys will bring to LGC. As a provider of biological materials and viral antigens, this latest acquisition enhances our infectious diseases portfolio, enabling us to become a true centre of excellence for our customers seeking a full-service source for virology-related products and services.”

LGC is actively seeking opportunities to strengthen its customer offering where it supports strategic growth priorities and is aligned to its purpose: Science for a Safer World.

Established in 1997 in Maryland, USA, Virusys has focused on the development of in vitro diagnostics (IVD), proteins and antibodies and built an enviable reputation for innovation, quality, and reliability across its broad customer base.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in